Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01177813 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Empagliflozin (BI 10773) Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes
A Phase 3 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 3
- Development phase
- 986
- Enrollment target
NCT01177813 is a Phase 3 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 986 participants.
The verdict
NCT01177813, a Phase 3 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 986 participants
- Enrollment target
Study Summary
The aim of this study is to investigate the efficacy, safety and tolerability of BI 10773 compared to placebo and sitagliptin given for 24 weeks as monotherapy in patients with T2DM with insufficient glycaemic control. For the open-label part of the study the objective is to estimate the efficacy and safety of BI 10773 when given for 24 weeks in patients with T2DM with very poor glycaemic control.
Interventions
- DRUG BI 10773
- DRUG Placebo identical to BI10773 high dose
- DRUG BI 10773 open label
- DRUG Placebo identical to BI10773 low dose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 986 participants |
| Start Date | 2010-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01177813
The ClinicalTrials.gov registry entry for NCT01177813 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 986 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which BI 10773 is the first listed.
NCT01177813 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01177813 about?
NCT01177813 is a clinical study titled "Efficacy and Safety of Empagliflozin (BI 10773) Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes". The aim of this study is to investigate the efficacy, safety and tolerability of BI 10773 compared to placebo and sitagliptin given for 24 weeks as monotherapy in patients with T2DM with insufficient glycaemic control. For the open-label part of the study the objective is to estimate the efficacy an...
What is the current status of trial NCT01177813?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 986 participants. The study started on 2010-07.
What interventions are being tested in trial NCT01177813?
The interventions under investigation include: BI 10773 (DRUG), Placebo identical to BI10773 high dose (DRUG), BI 10773 open label (DRUG), Placebo identical to BI10773 low dose (DRUG).
Who is sponsoring clinical trial NCT01177813?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.